What was BDX's revenue growth and the key drivers in the first quarter of 2008?

BDX reported a 14% increase in revenue to $1.706 billion for the first quarter of 2008. This growth was driven by a combination of a 9% increase in volume and a favorable foreign currency translation impact of approximately 6%. Growth was observed across all three segments: Medical, Diagnostics, and Biosciences.

How did BDX's profitability change compared to the prior year?

BDX saw a significant improvement in profitability. Net income rose to $271.5 million in Q1 2008, compared to $142.9 million in Q1 2007. This resulted in basic earnings per share increasing to $1.11 from $0.58 in the prior year.

What is the company's stance on its ongoing legal proceedings?

BDX acknowledges several ongoing legal proceedings, including antitrust claims, product liability suits, and patent infringement claims. While the company believes it has meritorious defenses and is vigorously defending itself, management notes that the uncertain nature of litigation means potential charges could arise that might materially affect consolidated results of operations and cash flows. However, specific new developments or material changes were not highlighted as significantly impacting the current quarter's financial results beyond general disclosures.

How is BDX managing increased costs, such as raw materials?

The company acknowledged higher resin purchase costs due to increased oil prices. For the reported quarter, these increases were largely offset by productivity improvements and cost reduction programs. However, management indicated that significant additional increases in resin costs could impact future operating results. Gross profit margin was also impacted by higher raw material and steel costs, as well as manufacturing startup costs.

BDX 10-Q Quarterly Report Q1 FY2008 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported strong first-quarter 2008 results, with revenues climbing 14% year-over-year to $1.706 billion, driven by a balanced performance across its Medical, Diagnostics, and Biosciences segments. Net income surged to $271.5 million, a significant increase from $142.9 million in the prior year, translating to basic earnings per share of $1.11. This growth was supported by a 9% volume increase and favorable foreign currency translation, which added approximately 6% to revenue. The company also demonstrated effective cost management, with selling and administrative expenses as a percentage of revenue decreasing, despite some headwinds from increased raw material costs and manufacturing startup expenses. The company continues to invest in research and development, with R&D expenses up 14% year-over-year, reflecting a commitment to innovation. Liquidity remains strong, evidenced by substantial cash flow from operations and a healthy debt-to-capital ratio. BDX also actively returned capital to shareholders through share repurchases. While facing some ongoing legal proceedings and increased raw material costs, management's outlook remains positive, with expectations for continued revenue and earnings growth, albeit with a slight anticipated decrease in gross profit margin due to cost pressures.

Key Highlights

1Total revenues increased by 14% to $1.706 billion in Q1 2008 compared to $1.501 billion in Q1 2007.
2Net income significantly improved, rising to $271.5 million from $142.9 million in the prior year period.
3Basic earnings per share (EPS) rose to $1.11 from $0.58 in the prior year, demonstrating strong profitability per share.
4All three business segments (Medical, Diagnostics, Biosciences) showed robust revenue growth, indicating diversified strength.
5Operating cash flow from continuing operations was strong at $473.1 million, up from $276.1 million in the prior year, indicating healthy cash generation.
6The company repurchased $122.7 million of its common stock during the quarter, signaling confidence and commitment to shareholder returns.
7Effective cost management was evident, with selling and administrative expenses decreasing as a percentage of revenue.

BECTON DICKINSON & CO Quarterly Report for Q1 Ended Dec 31, 2007

Summary

Key Highlights

Frequently Asked Questions